Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy D Henry

Showing results (471-480 of 573) with videos related to

Pageof 58
Sort By:
Circulation. Cardiovascular Interventions|March 9, 2016
Response to Letter Regarding Article, "Proton Pump Inhibitors, Platelet Reactivity, and Cardiovascular Outcomes After Drug-Eluting Stents in Clopidogrel-Treated Patients: The ADAPT-DES Study"Giora Weisz, Nathaniel R Smilowitz, Ajay J Kirtane, et al.
ESC Heart Failure|October 23, 2020
Cardiopoietic stem cell therapy in ischaemic heart failure: long-term clinical outcomesJozef Bartunek, Andre Terzic, Beth A Davison, et al.
Cardiovascular Research|August 13, 2021
Recommendations for nomenclature and definition of cell products intended for human cardiovascular useDoris A Taylor, Lourdes Chacon-Alberty, Luiz C Sampaio, et al.
Circulation|August 4, 2007
A regional system to provide timely access to percutaneous coronary intervention for ST-elevation myocardial infarctionTimothy D Henry, Scott W Sharkey, M Nicholas Burke, et al.
European Heart Journal|August 5, 2020
Intracoronary ALLogeneic heart STem cells to Achieve myocardial Regeneration (ALLSTAR): a randomized, placebo-controlled, double-blinded trialRaj R Makkar, Dean J Kereiakes, Frank Aguirre, et al.
JACC. Cardiovascular Interventions|August 7, 2017
Associations Between Chronic Kidney Disease and Outcomes With Use of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Report From the PROMETHEUS StudyUsman Baber, Jaya Chandrasekhar, Samantha Sartori, et al.
The New England Journal of Medicine|February 5, 2015
Efficacy of a device to narrow the coronary sinus in refractory anginaStefan Verheye, E Marc Jolicœur, Miles W Behan, et al.
European Heart Journal. Acute Cardiovascular Care|July 17, 2023
Thrombotic risk in patients with acute coronary syndromes discharged on prasugrel or clopidogrel: results from the PROMETHEUS studyMauro Chiarito, Davide Cao, Samantha Sartori, et al.
The American Journal of Cardiology|September 4, 2019
Association Between Hypertension, Platelet Reactivity, and the Risk of Adverse Events After Percutaneous Coronary Intervention (From the ADAPT-DES Study)Björn Redfors, Shmuel Chen, Ori Ben-Yehuda, et al.
International Journal of Cardiology|June 11, 2011
A randomized, controlled, multi-center trial comparing the safety and efficacy of zotarolimus-eluting and paclitaxel-eluting stents in de novo lesions in coronary arteries: final results of the ZoMaxx II trialWilliam A Gray, Alan C Yeung, Donald E Cutlip, et al.
Pageof 58

Showing results (471-480 of 573) with videos related to

Sort By:
Pageof 58
Circulation. Cardiovascular Interventions|March 9, 2016
Response to Letter Regarding Article, "Proton Pump Inhibitors, Platelet Reactivity, and Cardiovascular Outcomes After Drug-Eluting Stents in Clopidogrel-Treated Patients: The ADAPT-DES Study"Giora Weisz, Nathaniel R Smilowitz, Ajay J Kirtane, et al.
ESC Heart Failure|October 23, 2020
Cardiopoietic stem cell therapy in ischaemic heart failure: long-term clinical outcomesJozef Bartunek, Andre Terzic, Beth A Davison, et al.
Cardiovascular Research|August 13, 2021
Recommendations for nomenclature and definition of cell products intended for human cardiovascular useDoris A Taylor, Lourdes Chacon-Alberty, Luiz C Sampaio, et al.
Circulation|August 4, 2007
A regional system to provide timely access to percutaneous coronary intervention for ST-elevation myocardial infarctionTimothy D Henry, Scott W Sharkey, M Nicholas Burke, et al.
European Heart Journal|August 5, 2020
Intracoronary ALLogeneic heart STem cells to Achieve myocardial Regeneration (ALLSTAR): a randomized, placebo-controlled, double-blinded trialRaj R Makkar, Dean J Kereiakes, Frank Aguirre, et al.
JACC. Cardiovascular Interventions|August 7, 2017
Associations Between Chronic Kidney Disease and Outcomes With Use of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Report From the PROMETHEUS StudyUsman Baber, Jaya Chandrasekhar, Samantha Sartori, et al.
The New England Journal of Medicine|February 5, 2015
Efficacy of a device to narrow the coronary sinus in refractory anginaStefan Verheye, E Marc Jolicœur, Miles W Behan, et al.
European Heart Journal. Acute Cardiovascular Care|July 17, 2023
Thrombotic risk in patients with acute coronary syndromes discharged on prasugrel or clopidogrel: results from the PROMETHEUS studyMauro Chiarito, Davide Cao, Samantha Sartori, et al.
The American Journal of Cardiology|September 4, 2019
Association Between Hypertension, Platelet Reactivity, and the Risk of Adverse Events After Percutaneous Coronary Intervention (From the ADAPT-DES Study)Björn Redfors, Shmuel Chen, Ori Ben-Yehuda, et al.
International Journal of Cardiology|June 11, 2011
A randomized, controlled, multi-center trial comparing the safety and efficacy of zotarolimus-eluting and paclitaxel-eluting stents in de novo lesions in coronary arteries: final results of the ZoMaxx II trialWilliam A Gray, Alan C Yeung, Donald E Cutlip, et al.
Pageof 58